238 related articles for article (PubMed ID: 34330779)
1. Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression.
Lai SA; Gundlapalli H; Ekiz HA; Jiang A; Fernandez E; Welm AL
Cancer Discov; 2021 Dec; 11(12):3178-3197. PubMed ID: 34330779
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.
Eyob H; Ekiz HA; Derose YS; Waltz SE; Williams MA; Welm AL
Cancer Discov; 2013 Jul; 3(7):751-60. PubMed ID: 23612011
[TBL] [Abstract][Full Text] [Related]
4. RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses.
Eyob H; Ekiz HA; Welm AL
Oncoimmunology; 2013 Sep; 2(9):e25670. PubMed ID: 24327933
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.
Ekiz HA; Lai SA; Gundlapalli H; Haroun F; Williams MA; Welm AL
Oncoimmunology; 2018; 7(9):e1480286. PubMed ID: 30228950
[TBL] [Abstract][Full Text] [Related]
6. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
McClaine RJ; Marshall AM; Wagh PK; Waltz SE
Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
[TBL] [Abstract][Full Text] [Related]
7. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.
Bourn JR; Ruiz-Torres SJ; Hunt BG; Benight NM; Waltz SE
Cancer Lett; 2021 Apr; 503():75-90. PubMed ID: 33508385
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.
Yao HP; Zhuang CM; Zhou YQ; Zeng JY; Zhang RW; Wang MH
Curr Cancer Drug Targets; 2013 Jul; 13(6):686-97. PubMed ID: 23597200
[TBL] [Abstract][Full Text] [Related]
11. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
Thangasamy A; Rogge J; Ammanamanchi S
J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
[TBL] [Abstract][Full Text] [Related]
12. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
13. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Dustin D; Gu G; Beyer AR; Herzog SK; Edwards DG; Lin H; Gonzalez TL; Grimm SL; Coarfa C; Chan DW; Kim BJ; De La O JP; Ellis MJ; Liu D; Li S; Welm AL; Fuqua SAW
Br J Cancer; 2021 Jan; 124(1):191-206. PubMed ID: 33257837
[TBL] [Abstract][Full Text] [Related]
14. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
15. Short-form Ron receptor is required for normal IFN-gamma production in concanavalin A-induced acute liver injury.
Wetzel CC; Leonis MA; Dent A; Olson MA; Longmeier AM; Ney PA; Boivin GP; Kader SA; Caldwell CC; Degen SJ; Waltz SE
Am J Physiol Gastrointest Liver Physiol; 2007 Jan; 292(1):G253-61. PubMed ID: 17008558
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth.
Gurusamy D; Gray JK; Pathrose P; Kulkarni RM; Finkleman FD; Waltz SE
Cancer Res; 2013 Mar; 73(6):1752-63. PubMed ID: 23328584
[TBL] [Abstract][Full Text] [Related]
17. Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells.
Narasimhan M; Ammanamanchi S
Cancer Res; 2008 Jul; 68(13):5185-92. PubMed ID: 18593918
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
[TBL] [Abstract][Full Text] [Related]
19. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.
Wagh PK; Peace BE; Waltz SE
Adv Cancer Res; 2008; 100():1-33. PubMed ID: 18620091
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice.
Marshall AM; McClaine RJ; Gurusamy D; Gray JK; Lewnard KE; Khan SA; Waltz SE
Mol Cancer; 2012 Jan; 11():2. PubMed ID: 22226043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
